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Von Willebrand Disease
Introduction
Erik Von Willebrand was an internist who in the late 1900s took an interest in blood.
More specifically, he was interested in learning more about the blood’s ability to clot.
Throughout his works, Erik Von Willebrand identified a new disease. He stated it was quite
different from hemophilia and similar blood-clotting diseases in that this new disease had
characteristically extended time of bleeding. In some cases, this prolonged bleeding was
life-threatening (1). This new disease would go on to be named after him, Von Willebrand
Disease (VWD). A few years later, the gene affected by the disease was identified and
similarly named Von Willebrand Factor (VWF). VWF plays an important role in blood clotting
because it promotes platelet adhesion by binding to components of connective tissue,
glycoproteins on platelet surfaces, and clotting factors (2). To date, three types of VWD
exist, each one dependent on VWF levels and progressively more severe. Nevertheless, the
most common VWD symptoms are abnormal bleeding, blood in stool or urine, and
excessive bleeding (3).
Incidence
According to 2015 statistics from the Center for Disease Control, VWD affects over 3
million people in the United States alone (4). This is a number larger than the population of
21 of the 50 states of the United States. Along with hemophilia, VWD is the most common
inherited bleeding disorders that are found in hospital emergency rooms (5). Also, a report
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from the US Hemophilia Treatment Center recorded that from 1990-2010 VWD cases
increased by 148% (6).
Genetic Basis
As previously stated, VWF is the main protein affected in VWD. The DNA
sequence for VWF is found on chromosome 12; specifically, it is on the p13.3 location.
The sequence is on the negative DNA strand and is 175,797 base pairs long. The mRNA
transcribed, in turn, is 8833 base pairs long, consisting of 51 introns and 52 exons. The final
translated VWF protein is composed of 2,813 amino acids (7).
Domains. To understand both the importance and functionality of VWF it is
paramount to understand its protein domains. VWF protein is composed of fourteen domains in
the following order: D1-D2-D-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK (8). The first four
domains (D1, D2, D, and D3) serve in regulating the formation of multimers (multiple
monomers held together through noncovalent bonds). From these, the D and D3 domains
allow VWF to bind to Coagulation Factor VIII (FVIII) protein. FVIII is carried by VWF
throughout the bloodstream in its inactive form. When vascular injury occurs and coagulation is
needed, it is released from VWF into the affected area where it forms the FVIII/FIX complex
needed for coagulation (9, 10). The A1 domain of VWF allows the protein to bind GpIb.
GpIb is a glycoprotein found on the surface of platelets. The interaction stabilizes platelets and
in turn facilitates the interaction between platelet receptors and their ligands (11). The A3
domain is responsible for binding to collagen. Collagen is found in the subendothelial layers
of blood vessels. This allows VWF to anchor itself to the walls of blood vessels during
vascular injury. Alto gether, the domains found on the VWF allow it to carry FVIII to the
site of vascular injury, anchor itself to collagen on blood vessel walls, and promote
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aggregation of platelets for coagulation to occur. Figure 1 summarizes the functions of the
VWF domains.
Pathophysiology
Single-Nucleotide Mutations
Recent research has vastly aided in identifying a great range of genetic defect that
have direct implications on the phenotypes of the different types of VWD. As discussed in
the next section, VWD type 1 is the most common of all the types of VWD. For VWD
type 1, missense mutations account for approximately 80% of the mutations that lead to the
VWD type 1 phenotype. Missense mutations occur when there is a single nucleotide
substitution in the DNA code. This change of a nucleotide results in a codon that codes for
an amino acid different from the one coded by the non-mutated sequence (13). At least half of
these VWD type 1 missense mutations occur in exons 18-28. For example, in the normal,
unmutated sequence in base pair 3639 codes for the amino acid cysteine. In some cases, a
missense mutation of the cysteine results in a change from cysteine to guanine (C1130F
mutation). This particular mutation has been well documented in VWD type 1 (14). This
phenomenon does not only occur in VWD type 1. In VWD type 2 similar missense
mutations are responsible for the diseased phenotypes. Different types of missense mutations
have been linked to VWD type 2A, 2B, and 2N.

Fig. 1. The structure of VWF including domains and common locations of gene mutations of each
type of VWD (12).
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However, missense mutations are not the only causes of VWD. Null mutations, in
which there is a loss of function of the protein, such as deletion mutations and nonsense
mutations have been identified to account for 90% of the genetic and molecular defects
observed in VWD type 3. When a deletion occurs, a segment of the DNA sequence is lost.
This can occur in the form of loss of a single nucleotide or of loss of a larger portion of the
DNA sequence. In VWD, especially in VWD type 3, the most common type of deletion is a
loss of a single cysteine nucleotide of exon 18. This particular deletion has been observed in
48.3% of patients from Europe who were diagnosed with VWD type 3. Nonsense mutations
occur when a codon that would code for an amino acid in its unaltered state is changed to a
stop codon and translation is stopped prematurely. This causes a VWF protein that has not
been fully translated and thus will not carry out normal functions. All of the singlenucleotide mutations previously mentioned are examples of point mutations (15).
VWF Protein Domain Mutations
In addition to point mutations, studies have linked larger mutations of VWF protein
domains to the various phenotypes of VWD. For example, as previously stated, the D1
domain of VWF in involved in regulating the formation of multimers through non-covalent
bonds. A study concluded that mutations which are found in the D1 domain have been shown
to weaken the formation of multimers, reduce intracellular trafficking, as well as reduce the
secretion of VWF from the endothelial cells of the vascular tissue to the bloodstream (16).
A different study determined a similar pathological effect in which mutations of the A3
domain were found to cause VWD type 2M, a rare form of VWD type 2. The A3 domain
is normally attributed to binding of collagen. When these mutations occur in the domain,
however, there is a decreased VWF-dependent adhesion to platelets (17). Finally, a different
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set of mutations of the A3 domain caused a significant deficiency in the ability of VWF to
bind to collagen (18). Figure 1 contains information regarding where most mutations occur in
the VWF sequence for each type of VWD.
Pathology
VWD Type 1
There are three main types of VWD. Of these, VWD type 1 is the most common type of
VWD. While it is inherited as a trait that is autosomal dominant, the trait also has incomplete
penetrance. Thus, two affected alleles must be inherited in order to produce the VWD type 1
phenotype. VWD type 1 is characterized by a partial defect in VWF protein levels in the
blood. Hence, in VWD type 1 less VWF is found in circulation than what are considered
appropriate levels required for normal function. This is why VWD type 1 is referred to as a
partial quantitative defect of VWF. This quantitative defect itself does not pose a lifethreatening risk to the affected person. However, the affected person will take significantly
longer to clot a wound than an unaffected person (19).
VWD Type 2
Compared to VWD type 1, VWD type 2 is referred to as qualitative defects rather
than quantitative. In VWD type 2 VWF levels are considered to be in the normal range.
However, there is alteration of function of the protein. VWD type 2 is subdivided into four
subtypes (Type 2A, 2B, 2M, and 2N) each of these subtypes corresponds to a different
alteration of function of VWF. When VWD type 2A occurs, the affinity of VWF for platelet
glycoprotein GpIb is increased. Therefore, VWF will have greater adherence to platelets and
these affected VWF proteins will promote a larger platelet aggregation than would normally
occur. A danger of this VWD subtype is that the augmented aggregation of platelets can
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cause blockage (20).
In contrast, type 2B is characterized by a lower affinity of VWF to the platelet
glycoprotein GpIb. In this case, fewer VWF proteins will bind to the GpIb glycoprotein and
as a result platelet aggregation will be decreased. Therefore, the tissue exposed during
vascular injury will not clot properly. Similarly, in VWD type 2N the affinity of VWF to
FVIII is decreased. When this occurs, FVIII is not transported in sufficient quantities to the
affected area. Therefore, VWD type 2N results in a similar phenotype as VWD type 2B.
Finally, VWD Type 2M involves defects in VWF/platelet interactions. Since it is a rare form
of VWD, not much studies address this particular type. Nevertheless, existing research has
linked VWD type 2M to impaired binding to platelets as well as impaired binding to
collagen in vascular subendothelium (21).
VWD Type 3
VWD type 3 is the most severe type of VWD. Similar to VWD type 1, VWD type 3
is a quantitative type of VWD. This type of VWD is characterized by extremely low or
virtually non-existent levels of VWF in the bloodstream. Given this situation, in the presence
of vascular injury clotting will be absent or exceedingly limited. This proves to be lifethreatening in almost all circumstances.
Diagnosis
Although VWD is not a disease which occurs frequently, the Scientific and
Standardization Committee of the International Society on Thrombosis and Hemostasis stated
that VWD is more than likely underdiagnosed (22). Considering that bleeding symptoms are
quite common within even the unaffected population, VWD is difficult to properly diagnose.
However, certain predictors exist. For example, it has been documented that 47-60% of
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women who reported menstrual periods with prolonged and/or heavy bleeding (menorrhagia)
were later diagnosed with VWD. This was most prevalent in VWD type 3. Similarly, epistaxis
(nose-bleeds) was a highly reported symptom (55%) by people who would later be diagnosed
with VWD. Other symptoms frequently found in patients who are later diagnosed with VWD
include bleeding after a dental extraction and ecchymoses (skin discoloration that is normally
caused by bleeding that occurs underneath). Figure 2 indicates were these symptoms normally
occur in the human body.

Fig. 2. The location of the four most common symptoms of VWD. Epistaxis occurs in the nose, bleeding
occurs in the oral cavity during dental extraction, ecchymoses frequently occur in the limbs due to bruising, and
menorrhagia occurs only in women during menstrual periods as blood exits the vagina.

When making a diagnosis it is important to identify these and other common symptoms
as well as a personal and family history to assess the likelihood of the disease. Once these
steps have been done, a physical examination may be performed. The physical examination
itself should be done to 1) confirm evidence of recent bleeding and 2) find other probable
causes of such bleeding. Evidence for recent bleeding include petechiae, hematomas, and
ecchymoses among others. Other probable causes of bleeding that are looked for in the
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physical examination include arthropathy, laxity of joint and skin, signs of anemia,
splenomegaly, evidence of liver disease, lesions present in gynecologic examination, and
telangiectasia (23).
Laboratory
To date, there is no single laboratory test available that can screen for VWD. However,
to further confirm the diagnosis of VWD the first step is to do an initial evaluation of
hemostasis. These tests will only provide the physician with an idea of whether the symptoms
may be due to a deficiency in platelets (thrombocytopenia) or a deficiency in coagulation
factors. There are three tests that are performed in this step: a partial thromboplastin time
(PTT), a platelet count and complete blood count (CBC), and prothrombin time (PT). In
addition, an optional fibrinogen level or a thrombin time (TT) test can be done. If no
abnormalities are present in the test results or if there is a strong history of bleeding, the
initial VWD assays are performed.
The initial VWD assays are used in detecting VWD or low VWF. Each of the three
tests in step measure different aspects related to the disease. The VWF:Ag assay measures the
amount of VWF protein present in blood plasma; the VWF:RCo assay measures the
function of VWF when in it participates in ristocetin cofactor activity; and the FVIII assay
measures the ability of the VWF protein to serve as a carrier protein for FVIII. If an
abnormality is found in any of the tests, VWD is the most likely diagnosis and referral to a
coagulation specialist is recommended.
Treatment and Management
Treatment available to treat VWD is quite limited. Not enough research has been
conducted in terms of treatment due to the fact that there are not as many cases as other
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major diseases. Nevertheless, throughout the years there have been successful medications in
providing temporary relief of VWD symptoms.
Currently, the most widely used medication for treating VWD is desmopressin
(DDAVP). Desmopressin has been used for over twenty years to treat VWD.
Desmopressin works by binding to receptors on endothelial cells of blood vessel walls. This
causes the cascade release of the secondary messengers cyclic adenosine monophosphate. The
cascade then induces the exocytosis of VWF from the WeibelPalade bodies of endothelial cells
were VWF is stored. This mechanism also releases the VWF cargo protein FVIII. Therefore,
VWF and FVIII are then released into circulation and carry out their normal functions (24).
While desmopressin allows only temporary relief of VWD symptoms, it has proven
effective in reaching an appropriate level of important blood proteins. Desmopressin is used
for treating patients of VWD in a number of scenarios. For instance, desmopressin can be
used by patients of VWD who suffer from a bleeding gum. Desmopressin can also be used
by a VWD patient who will undergo a wisdom teeth surgery and there is significant
bleeding involved. In more serious scenarios, desmopressin is used by VWD patients during
major surgeries to prevent complications due to loss of blood and to promote proper healing.
Since desmopressin is only a temporary solution to VWD, patients must learn to manage
the disease. VWD patients are recommended not to participate in contact sports as these may
lead to bleeding or internal injuries. Depending on the severity of the disease many VWD
patients are advised to have a dose of desmopressin available in case of emergency. However,
desmopressin is available only by prescription. In addition, desmopressin can cost over $730
for 100 0.1 mg tablets and over $1,000 for 100 0.2 mg tablets (25).
Current Research
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ADAMTS-13 is a protein that has the ability to breakdown large and complex molecules
or proteolysis. Specifically, the protease ADAMTS-13 targets the VWF protein for degradation.
Researchers have then studied ADAMTS-13 and its role in VWD. These researchers have
found that inhibiting this VWF protease ADAMTS-13 yielded two results. First, they found
that the inhibition of ADAMTS-13 lead to less degradation of VWF, as expected.
Surprisingly, the researchers also found that this ADAMTS-13 inhibition actually lead to
improved function of VWF. Research continues along this field as it may prove to become a
novel treatment for VWD (26).
Another type of innovative research that is being con- ducted studies the effects of
lung transplants on VWD. These researchers used pig models to study VWD. They
performed lung transplants from control pigs to the pigs with the deficiency in VWF. The
studies they performed indicated that the pigs with low levels of VWF had significantly higher
levels of VWF after the surgery had been performed. The researchers were then able to
conclude that the reason for this occurrence is that the endothelial cells of the lungs naturally
secrete high levels of VWF (27). Research in this field continued and in 2015 a lung
transplant was performed in Spain on a 26-year old male with VWD type 1. The study found
that the levels of VWF in the blood increased during the days after the surgery. Surprisingly,
the VWF levels did not only increase post-surgery. Laboratory tests conducted during the
months and years following the surgery showed that these levels of VWF were maintained.
This is the first documented case of VWD having been corrected through a transplantation of
the lung (28).
Summary
VWD is a systemic, hereditary disease characterized by reduced levels of VWF in the
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bloodstream or loss of function of the VWF. VWD can present itself in three main types
(VWD type 1, 2, and 3) as well as four subtypes of VWD type 2 (VWD type 2A, 2B, 2N,
and 2M). VWD types 1 and 3 are characterized by reduced or severely reduced levels of the
VWF protein in the blood, respectively. VWD type 2 and its subtypes are associated with loss
of function of VWF. Mutations of the DNA code account for most the causes of all types of
VWD. Diagnosis of VWD involves a detailed family and personal history that could indicate
a hereditary disease, a physical examination to confirm recent bleeding and possible causes,
an initial examination of hemostasis that might indicate other causes, and a set of initial
VWD assays that could determine low levels of VWF protein in blood plasma.
Desmopressin is the most common treatment for VWD. Desmopressin temporarily induces
exocytosis of VWF into the bloodstream. Also, research is being conducted to provide a better
understanding of VWF-related proteins (ADAMTS-13) and of long-term treatment for VWD.
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